Compare Heron Therapeutics Inc (HRTX) vs Manhattan Associates Inc (MANH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Manhattan Associates Inc — how do they compare? Heron Therapeutics Inc trades at $0.41 (market cap $68.01M), while Manhattan Associates Inc trades at $204.89 (market cap $12.06B). The key difference: Manhattan Associates Inc is far larger — about 177.3× Heron Therapeutics Inc's market cap, and Manhattan Associates Inc is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Manhattan Associates Inc for 12 Days on average.
| HRTX | MANH | |
|---|---|---|
Market Cap | $68.01M | $12.06B |
Volume | 1,891,941 | 376,150 |
Sector | Health | Technology |
52-Week High | $1.49 | $223.76 |
52-Week Low | $0.27 | $120.88 |
Typical Hold Time | 35 Days | 12 Days |
Enterprise Value | $174.75M | $11.93B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.3582, down 8.15% today, with a bullish technical signal from moving averages but mixed earnings. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates, continuing a trend of net losses. Analyst sentiment remains strongly positive with 89% buy ratings, though Zacks issued a Strong Sell rating in July 2026.
The outlook hinges on revenue stabilization and path to profitability. Investment opportunity lies in analyst optimism and product sales growth, but risks include persistent losses, high valuation multiples, and competitive pressures in the biotechnology sector.
MANH trades at $206.78, up 2.31% today, with a bullish technical outlook as it sits above key support at $205. The company shows strong profitability with a net margin of 18.67% and has beaten earnings estimates for three consecutive quarters. Recent news includes a product launch of Editions for its solutions but also ongoing legal investigations into fiduciary duties.
The outlook is cautiously optimistic given analyst consensus of Buy and a $210.50 price target, though high valuation ratios and legal overhangs present risks. Earnings growth remains the key catalyst for further upside, but investors should weigh the elevated P/E of 59.26 against potential legal and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Manhattan Associates Inc
Manhattan Associates, Inc. is a global leader in supply chain and omnichannel commerce software. The company provides a comprehensive suite of cloud-based and on-premise solutions for warehouse management (WMS), transportation management (TMS), and order management (OMS). MANH's technology helps retailers, wholesalers, and manufacturers manage inventory, optimize logistics, and unify the shopping experience across physical and digital channels.
Read more on MANH →
